Epigenetic Alterations as Cancer Diagnostic, Prognostic, and Predictive Biomarkers

Advances in Genetics

Volumn 71, Issue C, 2010, Pages 125-176

  Deng, Dajun ^a   Liu, Zhaojun ^a   Du, Yantao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TUMOR MARKER;

CPG ISLAND; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NEOPLASM; PROGNOSIS; REVIEW;

CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957353074     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380864-6.00005-5     Document Type: Book

References (301)

1. Aggerholm A., Holm M.S., Guldberg P., Olesen L.H., Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur. J. Haematol. 2006, 76:23-32.
2. Agrelo R., Cheng W.H., Setien F., Ropero S., Espada J., Fraga M.F., Herranz M., Paz M.F., Sanchez-Cespedes M., Artiga M.J., et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl. Acad. Sci. USA 2006, 103:8822-8827.
3. Amara K., Trimeche M., Ziadi S., Laatiri A., Hachana M., Korbi S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann. Oncol. 2008, 19:1774-1786.
4. Ando T., Yoshida T., Enomoto S., Asada K., Tatematsu M., Ichinose M., Sugiyama T., Ushijima T. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: Its possible involvement in the formation of epigenetic field defect. Int. J. Cancer 2009, 124:2367-2374.
5. Aoki E., Uchida T., Ohashi H., Nagai H., Murase T., Ichikawa A., Yamao K., Hotta T., Kinoshita T., Saito H., et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia 2000, 14:586-593.
6. Ariel I., Ayesh S., Perlman E.J., Pizov G., Tanos V., Schneider T., Erdmann V.A., Podeh D., Komitowski D., Quasem A.S., et al. The product of the imprinted H19 gene is an oncofetal RNA. Mol. Pathol. 1997, 50:34-44.
7. Avissar M., McClean M.D., Kelsey K.T., Marsit C.J. MicroRNA expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis 2009, 30:2059-2063.
8. Avissar M., Christensen B.C., Kelsey K.T., Marsit C.J. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin. Cancer Res. 2009, 15:2850-2855.
9. Bai H., Gu L.K., Zhou J., Deng D.J. p16 hypermethylation during gastric carcinogenesis of Wistar rats by N-methyl-N'-nitro-N-nitrosoguanidine. Mutat. Res. 2003, 535:73-78.
10. Bai H., Zhou J., Deng D.J. Nucleosome positions and differential methylation status of various regions within the MLH1 CpG island. Chin. J. Cancer Res. 2008, 20:237-242.
11. Balaña C., Ramirez J.L., Taron M., Roussos Y., Ariza A., Ballester R., Sarries C., Mendez P., Sanchez J.J., Rosell R. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1, 3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin. Cancer Res. 2003, 9:1461-1468.
12. Bandrés E., Cubedo E., Agirre X., Malumbres R., Zárate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzó M., et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer 2006, 5:29.
13. Bandres E., Agirre X., Bitarte N., Ramirez N., Zarate R., Roman-Gomez J., Prosper F., Garcia-Foncillas J. Epigenetic regulation of microRNA expression in colorectal cancer. Int. J. Cancer 2009, 125:2737-2743.
14. Bastian P.J., Ellinger J., Wellmann A., Wernert N., Heukamp L.C., Müller S.C., von Ruecker A. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin. Cancer Res. 2005, 11:4097-4106.
15. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E., Baylin S.B., Herman J.G. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA 1998, 95:11891-11896.
16. Belinsky S.A., Snow S.S., Nikula K.J., Finch G.L., Tellez C.S., Palmisano W.A. Aberrant CpG island methylation of the p16(INK4a) and estrogen receptor genes in rat lung tumors induced by particulate carcinogens. Carcinogenesis 2002, 23:335-339.
17. Belinsky S.A., Liechty K.C., Gentry F.D., Wolf H.J., Rogers J., Vu K., Haney J., Kennedy T.C., Hirsch F.R., Miller Y., et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006, 66:3338-3344.
18. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
19. Bialik S., Kimchi A. The death-associated protein kinases: Structure, function, and beyond. Annu. Rev. Biochem. 2006, 75:189-210.
20. Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463:893-898.
21. Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., Liu C.G., Bhatt D., Taccioli C., Croce C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901-1908.
22. Brabender J., Usadel H., Danenberg K.D., Metzger R., Schneider P.M., Lord R.V., Wickramasinghe K., Lum C.E., Park J., Salonga D., et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001, 20:3528-3532.
23. Brabender J., Usadel H., Metzger R., Schneider P.M., Park J., Salonga D., Tsao-Wei D.D., Groshen S., Lord R.V., Takebe N., et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin. Cancer Res. 2003, 9:223-227.
24. Brock M.V., Gou M., Akiyama Y., Muller A., Wu T.T., Montgomery E., Deasel M., Germonpre P., Rubinson L., Heitmiller R.F., et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin. Cancer Res. 2003, 9:2912-2919.
25. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., Glöckner S., Piantadosi S., Gabrielson E., Pridham G., et al. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 2008, 358:1118-1128.
26. Brouha B., Schustak J., Badge R.M., Lutz-Prigge S., Farley A.H., Moran J.V., Kazazian H.H. Hot L1s account for the bulk of retrotransposition in the human population. Proc. Natl. Acad. Sci. USA 2003, 100:5280-5285.
27. Buckingham L., Penfield F.L., Kim A., Liptay M., Barger C., Basu S., Fidler M., Walters K., Bonomi P., Coon J. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int. J. Cancer 2010, 126:1630-1639.
28. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99:15524-15529.
29. Camps C., Buffa F.M., Colella S., Moore J., Sotiriou C., Sheldon H., Harris A.L., Gleadle J.M., Ragoussis J. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 2008, 14:1340-1348.
30. Cao J., Zhou J., Gao Y., Gu L., Meng H., Liu H., Deng D. Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: A prospective cohort study. Clin. Cancer Res. 2009, 15:5178-5183.
31. Capel E., Fléjou J.F., Hamelin R. Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis. Oncogene 2007, 26:7596-7600.
32. Chan M.W., Chan L.W., Tang N.L., Tong J.H., Lo K.W., Lee T.L., Cheung H.Y., Wong W.S., Chan P.S., Lai F.M., et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 2002, 8:464-470.
33. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65:6029-6033.
34. Chang Y.S., Wang L., Liu D., Mao L., Hong W.K., Khuri F.R., Lee H.Y. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin. Cancer Res. 2002, 8:3669-3675.
35. Chen H., Wu S. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes. Chin. Med. J. (Engl.) 2002, 115:987-990.
36. Chen W.D., Han Z.J., Skoletsky J., Olson J., Sah J., Myeroff L., Platzer P., Lu S., Dawson D., Willis J., et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. 2005, 97:1124-1132.
37. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
38. Childs G., Fazzari M., Kung G., Kawachi N., Brandwein-Gensler M., McLemore M., Chen Q., Burk R.D., Smith R.V., Prystowsky M.B., et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol. 2009, 174:736-745.
39. Choma D., Daures J.P., Quantin X., Pujol J.L. Aneuploidy and prognosis of non-small-cell lung cancer: A meta-analysis of published data. Br. J. Cancer 2001, 85:14-22.
40. Cohen O., Inbal B., Kissil J.L., Raveh T., Berissi H., Spivak-Kroizaman T., Feinstein E., Kimchi A. DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J. Cell Biol. 1999, 146:141-148.
41. Creighton C.J., Fountain M.D., Yu Z., Nagaraja A.K., Zhu H., Khan M., Olokpa E., Zariff A., Gunaratne P.H., Matzuk M.M., et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 2010, 70:1906-1915.
42. Dansranjavin T., Mobius C., Tannapfel A., Bartels M., Wittekind C., Hauss J., Witzigmann H. E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. Oncol. Rep. 2006, 15:1125-1131.
43. Darr H., Benvenisty N. Factors involved in selfrenewal and pluripotency of embryonic stem cells. Handb. Exp. Pharmacol. 2006, 174:1-19.
44. Daskalos A., Nikolaidis G., Xinarianos G., Savvari P., Cassidy A., Zakopoulou R., Kotsinas A., Gorgoulis V., Field J.K., Liloglou T. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int. J. Cancer 2009, 124:81-87.
45. Deininger P.L., Moran J.V., Batzer M.A., Kazazian H.H. Mobile elements and mammalian genome evolution. Curr. Opin. Genet. Dev. 2003, 13:651-658.
46. Deiss L.P., Feinstein E., Berissi H., Cohen O., Kimchi A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev. 1995, 9:15-30.
47. Dejeux E., Rønneberg J.A., Solvang H., Bukholm I., Geisler S., Aas T., Gut I.G., Børresen-Dale A.L., Lønning P.E., Kristensen V.N., et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol. Cancer 2010, 9:68.
48. Deng G., Chen A., Hong J., Chae H.S., Kim Y.S. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999, 59:2029-2033.
49. Deng G., Peng E., Gum J., Terdiman J., Sleisenger M., Kim Y.S. Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br. J. Cancer 2002, 86:574-579.
50. Deng D.J., Zhou J., Zhu B.D., Ji J.F., Harper J.C., Powell S.M. Silencing-specific methylation and single nucleotide polymorphism of hMLH1 promoter in gastric carcinomas. World J. Gastroenterol. 2003, 9:26-29.
51. Deng D., El-Rifai W., Ji J., Zhu B., Trampont P., Li J., Smith M.F., Powel S.M. Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis 2003, 24:25-29.
52. deVos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K.V., Grützmann R., Pilarsky C., Habermann J.K., et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 2009, 55:1337-1346.
53. Dewannieux M., Esnault C., Heidmann T. LINE-mediated retrotransposition of marked Alu sequences. Nat. Genet. 2003, 35:41-48.
54. Dong C.X., Deng D.J., Pan K.F., Zhang L., Zhang Y., Zhou J., You W.C. Promoter methylation of p16 associated with Helicobacter pylori infection in precancerous gastric lesions: A population-based study. Int. J. Cancer 2009, 124:434-439.
55. Du L., Pertsemlidis A. microRNAs and lung cancer: Tumors and 22-mers. Cancer Metastasis Rev. 2010, 29:109-122.
56. Ehrlich M. DNA methylation in cancer: Too much, but also too little. Oncogene 2002, 21:5400-5413.
57. Ellinger J., Kahl P., von der Gathen J., Rogenhofer S., Heukamp L.C., Gütgemann I., Walter B., Hofstädter F., Büttner R., Müller S.C., et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010, 70:61-69.
58. Esteller M. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 2002, 21:5427-5440.
59. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
60. Esteller M., Hamilton S.R., Burger P.C., Baylin S.B., Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59:793-797.
61. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343:1350-1354.
62. Felsberg J., Rapp M., Loeser S., Fimmers R., Stummer W., Goeppert M., Steiger H.J., Friedensdorf B., Reifenberger G., Sabel M.C. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin. Cancer Res. 2009, 15:6683-6693.
63. Ferreri A.J., Dell'Oro S., Capello D., Ponzoni M., Iuzzolino P., Rossi D., Pasini F., Ambrosetti A., Orvieto E., Ferrarese F., et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br. J. Haematol. 2004, 126:657-664.
64. Fiegl H., Millinger S., Goebel G., Muller-Holzner E., Marth C., Laird P.W., Widschwendter M. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: Association with HER-2/neu status in primary breast cancer. Cancer Res. 2006, 66:29-33.
65. Figueroa M.E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P.J., Schifano E., Booth J., van Putten W., Skrabanek L., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
66. Friedrich M.G., Weisenberger D.J., Cheng J.C., Chandrasoma S., Siegmund K.D., Gonzalgo M.L., Toma M.I., Huland H., Yoo C., Tsai Y.C., et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 2004, 10:7457-7465.
67. Gao W., Yu Y., Cao H., Shen H., Li X., Pan S., Shu Y. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed. Pharmacother. 2010, 10.1016/j.biopha.2010.01.018.
68. Gerson S.L. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 2004, 4:296-307.
69. Gifford G., Paul J., Vasey P.A., Kaye S.B., Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 2004, 10:4420-4426.
70. Girault I., Tozlu S., Lidereau R., Bièche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin. Cancer Res. 2003, 9:4415-4422.
71. Gonzalgo M.L., Pavlovich C.P., Lee S.M., Nelson W.G. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 2003, 9:2673-2677.
72. Goto T., Mizukami H., Shirahata A., Sakata M., Saito M., Ishibashi K., Kigawa G., Nemoto H., Sanada Y., Hibi K. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer. Anticancer Res. 2009, 29:275-277.
73. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. miRBase: Tools for microRNA genomics. Nucleic Acids Res. 2008, 36:D154-D158. (Database issue).
74. Grombacher T., Mitra S., Kaina B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 1996, 17:2329-2336.
75. Grützmann R., Molnar B., Pilarsky C., Habermann J.K., Schlag P.M., Saeger H.D., Miehlke S., Stolz T., Model F., Roblick U.J., et al. Sensitive detection of colorectal cancer in peripheral blood by Septin 9 DNA methylation assay. PLoS ONE 2008, 3:e3759.
76. Günther T., Schneider-Stock R., Pross M., Manger T., Malfertheiner P., Lippert H., Roessner A. Alterations of the p16/MTS1-tumor suppressor gene in gastric cancer. Pathol. Res. Pract. 1998, 194:809-813.
77. Gurrieri F., Accadia M. Genetic imprinting: The paradigm of Prader-Willi and Angelman syndromes. Endocr. Dev. 2009, 14:20-28.
78. Hall P.A., Russell S.E. The pathobiology of the septin gene family. J. Pathol. 2004, 204:489-505.
79. Hall P.A., Jung K., Hillan K.J., Russell S.E. Expression profiling the human septin gene family. J. Pathol. 2005, 206:269-278.
80. Hall G.L., Shaw R.J., Field E.A., Rogers S.N., Sutton D.N., Woolgar J.A., Lowe D., Liloglou T., Field J.K., Risk J.M. p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2174-2179.
81. Harden S.V., Tokumaru Y., Westra W.H., Goodman S., Ahrendt S.A., Yang S.C., Sidransky D. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin. Cancer Res. 2003, 9:1370-1375.
82. Hegi M.E., Diserens A.C., Godard S., Dietrich P.Y., Regli L., Ostermann S., Otten P., Van Melle G., de Tribolet N., Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 2004, 10:1871-1874.
83. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J. Med. 2005, 352:997-1003.
84. Herbst A., Wallner M., Rahmig K., Stieber P., Crispin A., Lamerz R., Kolligs F.T. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur. J. Gastroenterol. Hepatol. 2009, 21:565-569.
85. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J. Med. 2003, 349:2042-2054.
86. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.-P.J., Markowitz S., Willson J.K.V., Hamilton S.R., Kinzler K.W., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 1998, 95:6870-6875.
87. Hernandez-Vargas H., Lambert M.-P., Le Calvez-Kelm F., Gouysse G., McKay-Chopin S., Tavtigian S.V., Scoazec J.-Y., Hercep Z. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS ONE 2010, 5:e9749.
88. Hitchins M.P., Ward R.L. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J. Med. Genet. 2009, 46:793-802.
89. Hitchins M.P., Wong J.J.L., Suthers G., Suter C.M., Martin D.I.K., Hawkins N.J., Ward R.L. Inheritance of a cancer-associated MLH1 germ-line epimutation. N. Engl. J. Med. 2007, 356:697-705.
90. Ho A.S., Huang X., Cao H., Christman-Skieller C., Bennewith K., Le Q.T., Koong A.C. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl. Oncol. 2010, 3:109-113.
91. Hoque M.O., Begum S., Topaloglu O., Chatterjee A., Rosenbaum E., Van Criekinge W., Westra W.H., Schoenberg M., Zahurak M., Goodman S.N., et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst. 2006, 98:996-1004.
92. Hoque M.O., Begum S., Brait M., Jeronimo C., Zahurak M., Ostrow K.L., Rosenbaum E., Trock B., Westra W.H., Schoenberg M., et al. Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J. Urol. 2008, 179:743-747.
93. Houbaviy H.B., Murray M.F., Sharp P.A. Embryonic stem cell-specific MicroRNAs. Dev. Cell 2003, 5:351-358.
94. House M.G., Guo M., Efron D.T., Lillemoe K.D., Cameron J.L., Syphard J.E., Hooker C.M., Abraham S.C., Montgomery E.A., Herman J.G., et al. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J. Gastrointest. Surg. 2003, 7:1004-1014.
95. Hu S., Wang X., Zhou J., Chen F., Zhang X., Chen W., Pan Q., Zhao F., Deng D., Qiao Y. Natural History of low-grade cervical intraepithelial neoplasia and its relationship with p16 hypermethylation. Chin. Cancer 2009, 18:420-423.
96. Iliopoulos D., Oikonomou P., Messinis I., Tsezou A. Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression. Oncol. Rep. 2009, 22:199-204.
97. Inbal B., Bialik S., Sabanay I., Shani G., Kimchi A. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J. Cell Biol. 2002, 157:455-468.
98. Iorio M.V., Casalini P., Tagliabue E., Ménard S., Croce C.M. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur. J. Cancer 2008, 44:2753-2759.
99. Iorns E., Turner N.C., Elliott R., Syed N., Garrone O., Gasco M., Tutt A.N., Crook T., Lord C.J., Ashworth A. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008, 13:91-104.
100. Issa J.P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004, 4:988-993.
101. Issa J.P., Gharibyan V., Cortes J., Jelinek J., Morris G., Verstovsek S., Talpaz M., Garcia-Manero G., Kantarjian H.M. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. 2005, 23:3948-3956.
102. Jang C.W., Chen C.H., Chen C.C., Chen J.Y., Su Y.H., Chen R.H. TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat. Cell Biol. 2002, 4:51-58.
103. Jarmalaite S., Jankevicius F., Kurgonaite K., Suziedelis K., Mutanen P., Husgafvel-Pursiainen K. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 2008, 75:145-151.
104. Jerónimo C., Henrique R., Hoque M.O., Mambo E., Ribeiro F.R., Varzim G., Oliveira J., Teixeira M.R., Lopes C., Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 2004, 10:8472-8478.
105. Jiang Y., Dunbar A., Gondek L.P., Mohan S., Rataul M., O'Keefe C., Sekeres M., Saunthararajah Y., Maciejewski J.P. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009, 113:1315-1325.
106. Jicai Z., Zongtao Y., Jun L., Haiping L., Jianmin W., Lihua H. Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma. Mol. Carcinog. 2006, 45:530-536.
107. Jin Z., Cheng Y., Gu W., Zheng Y., Sato F., Mori Y., Olaru A.V., Paun B.C., Yang J., Kan T., et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 2009, 69:4112-4115.
108. Kalikin L.M., Sims H.L., Petty E.M. Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors. Genomics 2000, 63:165-172.
109. Karray-Chouayekh S., Trifa F., Khabir A., Boujelbane N., Sellami-Boudawara T., Daoud J., Frikha M., Gargouri A., Mokdad-Gargouri R. Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma. J. Biomed. Biotechnol. 2009, 2009, 369129.
110. Kato K., Iida S., Uetake H., Takagi Y., Yamashita T., Inokuchi M., Yamada H., Kojima K., Sugihara K. Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int. J. Cancer 2008, 122:603-608.
111. Kawakami K., Brabender J., Lord R.V., Groshen S., Greenwald B.D., Krasna M.J., Yin J., Fleisher A.S., Abraham J.M., Beer D.G., et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 2000, 92:1805-1811.
112. Kazazian H.H., Goodier J.L. LINE drive. retrotransposition and genome instability. Cell 2002, 110:277-280.
113. Khleif S.N., DeGregori J., Yee C.L., Otterson G.A., Kaye F.J., Nevins J.R., Howley P.M. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc. Natl. Acad. Sci. USA 1996, 93:4350-4354.
114. Kim D.H., Nelson H.H., Wiencke J.K., Christiani D.C., Wain J.C., Mark E.J., Kelsey K.T. Promoter methylation of DAP-kinase: Association with advanced stage in non-small cell lung cancer. Oncogene 2001, 20:1765-1770.
115. Kim D.S., Kim M.J., Lee J.Y., Kim Y.Z., Kim E.J., Park J.Y. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer 2007, 110:2785-2792.
116. Kim E.J., Kim Y.J., Jeong P., Ha Y.S., Bae S.C., Kim W.J. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J. Urol. 2008, 180:1141-1145.
117. Kim M.S., Lee J., Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010, 29:181-206.
118. Kito H., Suzuki H., Ichikawa T., Sekita N., Kamiya N., Akakura K., Igarashi T., Nakayama T., Watanabe M., Harigaya K., et al. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate 2001, 49:110-115.
119. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 10.1074/jbc.M110.107821.
120. Koul S., McKiernan J.M., Narayan G., Houldsworth J., Bacik J., Dobrzynski D.L., Assaad A.M., Mansukhani M., Reuter V.E., Bosl G.J., et al. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol. Cancer 2004, 3:16.
121. Krishnamurthy J., Ramsey M.R., Ligon K.L., Torrice C., Koh A., Bonner-Weir S., Sharpless N.E. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006, 443:453-457.
122. Kronenwett U., Ploner A., Zetterberg A., Bergh J., Hall P., Auer G., Pawitan Y. Genomic instability and prognosis in breast carcinomas. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1630-1635.
123. Krusche C.A., Wülfing P., Kersting C., Vloet A., Böcker W., Kiesel L., Beier H.M., Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: A tissue microarray analysis. Breast Cancer Res. Treat. 2005, 90:15-23.
124. Kukitsu T., Takayama T., Miyanishi K., Nobuoka A., Katsuki S., Sato Y., Takimoto R., Matsunaga T., Kato J., Sonoda T., et al. Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis. Clin. Cancer Res. 2008, 14:48-54.
125. Landi M.T., Zhao Y., Rotunno M., Koshiol J., Liu H., Bergen A.W., Rubagotti M., Goldstein A.M., Linnoila I., Marincola F.M., et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 2010, 16:430-441.
126. Lawrie C.H., Soneji S., Marafioti T., Cooper C.D., Palazzo S., Paterson J.C., Cattan H., Enver T., Mager R., Boultwood J., et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int. J. Cancer 2008, 121:1156-1161.
127. Lee J.T., Lu N. Targeted mutagenesis of Tsix leads to nonrandom X inactivation. Cell 1999, 99:47-57.
128. Lee Y.Y., Kang S.H., Seo J.Y., Jung C.W., Lee K.U., Choe K.J., Kim B.K., Kim N.K., Koeffler H.P., Bang Y.J. Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. Cancer 1997, 80:1889-1896.
129. Li Q., Kopecky K.J., Mohan A., Willman C.L., Appelbaum F.R., Weick J.K., Issa J.P. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin. Cancer Res. 1999, 5:1077-1084.
130. Li L.C., Chui R., Nakajima K., Oh B.R., Au H.C., Dahiya R. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res. 2000, 60:702-706.
131. Licchesi J.D., Westra W.H., Hooker C.M., Herman J.G. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin. Cancer Res. 2008, 14:2570-2578.
132. Lin R.K., Hsu H.S., Chang J.W., Chen C.Y., Chen J.T., Wang Y.C. Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer 2007, 55:205-213.
133. Lin J.C., Jeong S., Liang G., Takai D., Fatemi M., Tsai Y.C., Egger G., Gal-Yam E.N., Jones P.A. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 2007, 12:432-444.
134. Liu Y., Zhang L., Ren H., Zhang G., Qin F., Kong G., Deng G., Ji J. Promoter hypermethylation of the p16 gene in pre- and post-gastrectomy plasma of patients with gastric carcinoma. J. Peking Univ. Health Sci. 2005, 37:257-260.
135. Liu B.L., Cheng J.X., Zhang W., Zhang X., Wang R., Lin H., Huo J.L., Cheng H. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol. 2010, 10.1093/neuonc/nop064.
136. Liu C.J., Kao S.Y., Tu H.F., Tsai M.M., Chang K.W., Lin S.C. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010, 10.1111/j.1601-0825.2009.01646.x.
137. Liu C.J., Tsai M.M., Hung P.S., Kao S.Y., Liu T.Y., Wu K.J., Chiou S.H., Lin S.C., Chang K.W. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010, 70:1635-1644.
138. Liu X., Sempere L.F., Ouyang H., Memoli V.A., Andrew A.S., Luo Y., Demidenko E., Korc M., Shi W., Preis M., et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest. 2010, 120:1298-1309.
139. Lodes M.J., Caraballo M., Suciu D., Munro S., Kumar A., Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 2009, 4:e6229.
140. Lofton-Day C., Model F., DeVos T., Tetzner R., Distler J., Schuster M., Song X., Lesche R., Liebenberg V., Ebert M., et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 2008, 54(2):414-423.
141. López M., Aguirre J.M., Cuevas N., Anzola M., Videgain J., Aguirregaviria J., Martínez de Pancorbo M. Gene promoter hypermethylation in oral rinses of leukoplakia patients-A diagnostic and/or prognostic tool?. Eur. J. Cancer 2003, 39:2306-2309.
142. Lu C., Soria J.C., Tang X., Xu X.C., Wang L., Mao L., Lotan R., Kemp B., Bekele B.N., Feng L., et al. Prognostic factors in resected stage I non-small-cell lung cancer: A multivariate analysis of six molecular markers. J. Clin. Oncol. 2004, 22:4575-4583.
143. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
144. Lu L., Katsaros D., de la Longrais I.A., Sochirca O., Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007, 67:10117-10122.
145. Lujambio A., Calin G.A., Villanueva A., Ropero S., Sánchez-Céspedes M., Blanco D., Montuenga L.M., Rossi S., Nicoloso M.S., Faller W.J., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. USA 2008, 105:13556-13561.
146. Luo D., Zhang B., Lv L., Xiang S., Liu Y., Ji J., Deng D. Methylation of CpG islands of p16 associated with progression of primary gastric carcinomas. Lab. Invest. 2006, 86:591-598.
147. Machida E.O., Brock M.V., Hooker C.M., Nakayama J., Ishida A., Amano J., Picchi M.A., Belinsky S.A., Herman J.G., Taniguchi S., et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res. 2006, 66:6210-6218.
148. Makarla P.B., Saboorian M.H., Ashfaq R., Toyooka K.O., Toyooka S., Minna J.D., Gazdar A.F., Schorge J.O. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin. Cancer Res. 2005, 11:5365-6369.
149. Malumbres R., Sarosiek K.A., Cubedo E., Ruiz J.W., Jiang X., Gascoyne R.D., Tibshirani R., Lossos I.S. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009, 113:3754-3764.
150. Manuyakorn A., Paulus R., Farrell J., Dawson N.A., Tze S., Cheung-Lau G., Hines O.J., Reber H., Seligson D.B., Horvath S. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: Results from RTOG 9704. J. Clin. Oncol. 2010, 28:1358-1365.
151. Mao L., Lee J.S., Fan Y.H., Ro J.Y., Batsakis J.G., Lippman S., Hittelman W., Hong W.K. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat. Med. 1996, 2:682-685.
152. Markou A., Tsaroucha E.G., Kaklamanis L., Fotinou M., Georgoulias V., Lianidou E.S. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem. 2008, 54:1696-1704.
153. Maruyama R., Sugio K., Yoshino I., Maehara Y., Gazdar A.F. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 2004, 100:1472-1477.
154. Mathé E.A., Nguyen G.H., Bowman E.D., Zhao Y., Budhu A., Schetter A.J., Braun R., Reimers M., Kumamoto K., Hughes D., et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin. Cancer Res. 2009, 15:6192-6200.
155. Matouk I.J., DeGroot N., Mezan S., Ayesh S., Abu-lail R., Hochberg A., Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE 2007, 2:e845.
156. Matsuda Y., Ichida T., Matsuzawa J., Sugimura K., Asakura H. p16 (INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999, 116:394-400.
157. McCabe M.T., Brandes J.C., Vertino P.M. Cancer DNA methylation: Molecular mechanisms and clinical implications. Clin. Cancer Res. 2009, 15:3927-3937.
158. McDade S.S., Hall P.A., Russell S.E. Translational control of SEPT9 isoforms is perturbed in disease. Hum. Mol. Genet. 2007, 16:742-752.
159. Mei M., Deng D., Liu T.H., Sang X.T., Lu X., Xiang H.D., Zhou J., Wu H., Yang Y., Chen J., et al. Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. J. Clin. Endocrinol. Metab. 2009, 94:3448-3457.
160. Meng F., Henson R., Lang M., Wehbe H., Maheshwari S., Mendell J.T., Jiang J., Schmittgen T.D., Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129.
161. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
162. Menigatti M., Truninger K., Gebbers J.O., Marbet U., Marra G., Schär P. Normal colorectal mucosa exhibits sex- and segment-specific susceptibility to DNA methylation at the hMLH1 and MGMT promoters. Oncogene 2009, 28:899-909.
163. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D. 5-prime CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1995, 1:686-692.
164. Michie A.M., McCaig A.M., Nakagawa R., Vukovic M. Death-associated protein kinase (DAPK) and signal transduction: Regulation in cancer. FEBS J. 2010, 277:74-80.
165. Mirnezami A.H., Pickard K., Zhang L., Primrose J.N., Packham G. MicroRNAs: Key players in carcinogenesis and novel therapeutic targets. Eur. J. Surg. Oncol. 2009, 35:339-347.
166. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105:10513-10518.
167. Moriyama T., Matsumoto T., Nakamura S., Jo Y., Mibu R., Yao T., Iida M. Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. Dis. Colon Rectum 2007, 50:1384-1392.
168. Motoyama K., Inoue H., Takatsuno Y., Tanaka F., Mimori K., Uetake H., Sugihara K., Mori M. Over- and under-expressed microRNAs in human colorectal cancer. Int. J. Oncol. 2009, 34:1069-1075.
169. Musolino C., Sant'antonio E., Penna G., Alonci A., Russo S., Granata A., Allegra A. Epigenetic therapy in myelodysplastic syndromes. Eur. J. Haematol. 2010, 10.1111/j.1600-0609.2010.01433.x.
170. Nairz K., Rottig C., Rintelen F., Zdobnov E., Moser M., Hafen E. Overgrowth caused by misexpression of a microRNA with dispensable wild-type function. Dev. Biol. 2006, 291:314-324.
171. Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., Kim J.W., Kim S. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 2008, 14:2690-2695.
172. Negri G., Vittadello F., Romano F., Kasal A., Rivasi F., Girlando S., Mian C., Egarter-Vigl E. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch. 2004, 445:616-620.
173. Nehls K., Vinokurova S., Schmidt D., Kommoss F., Reuschenbach M., Kisseljov F., Einenkel J., von Knebel Doeberitz M., Wentzensen N. p16 methylation does not affect protein expression in cervical carcinogenesis. Eur. J. Cancer 2008, 44:2496-2505.
174. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., Poon T.C., Ng S.S., Sung J.J. Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
175. Nikiforova M.N., Tseng G.C., Steward D., Diorio D., Nikiforov Y.E. MicroRNA expression profiling of thyroid tumors: Biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 2008, 93:1600-1608.
176. Nishida N., Fukuda Y., Komeda T., Kita R., Sando T., Furukawa M., Amenomori M., Shibagaki I., Nakao K., Ikenaga M., et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994, 54:3107-3110.
177. Nosho K., Irahara N., Shima K., Kure S., Kirkner G.J., Schernhammer E.S., Hazra A., Hunter D.J., Quackenbush J., Spiegelman D., et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008, 3:e3698.
178. Nuovo G.J., Plaia T.W., Belinsky S.A., Baylin S.B., Herman J.G. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl. Acad. Sci. USA 1999, 96:12754-12759.
179. Ogino S., Nosho K., Kirkner G.J., Kawasaki T., Chan A.T., Schernhammer E.S., Giovannucci E.L., Fuchs C.S. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl. Cancer Inst. 2008, 100:1734-1738.
180. Oh B.K., Kim H., Park H.J., Shim Y.H., Choi J., Park C., Park Y.N. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int. J. Mol. Med. 2007, 20:65-73.
181. Oki Y., Jelinek J., Shen L., Kantarjian H.M., Issa J.P. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 2008, 111:2382-2384.
182. Oshimo Y., Kuraoka K., Nakayama H., Kitadai Y., Yoshida K., Chayama K., Yasui W. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int. J. Cancer 2004, 112:1003-1009.
183. Ota N., Kawakami K., Okuda T., Takehara A., Hiranuma C., Oyama K., Ota Y., Oda M., Watanabe G. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis. Anticancer Res. 2006, 26:3729-3732.
184. Papadopoulos N., Nicolaides N.C., Wei Y.-F., Ruben S.M., Carter K.C., Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994, 263:1625-1629.
185. Pass H.I., Goparaju C., Ivanov S., Donington J., Carbone M., Hoshen M., Cohen D., Chajut A., Rosenwald S., Dan H., et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010, 70:1916-1924.
186. Pattamadilok J., Huapai N., Rattanatanyong P., Vasurattana A., Triratanachat S., Tresukosol D., Mutirangura A. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int. J. Gynecol. Cancer 2008, 18:711-717.
187. Pfeifer K., Leighton P.A., Tilghman S.M. The structural H19 gene is required for transgene imprinting. Proc. Natl. Acad. Sci. USA 1996, 93:13876-13883.
188. Pfister S., Rea S., Taipale M., Mendrzyk F., Straub B., Ittrich C., Thuerigen O., Sinn H.P., Akhtar A., Lichter P. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int. J. Cancer 2008, 122:1207-1213.
189. Pogribny I.P., James S.J. De novo methylation of the p16INK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats. Cancer Lett. 2002, 187:69-75.
190. Poynter J.N., Siegmund K.D., Weisenberger D.J., Long T.I., Thibodeau S.N., Lindor N., Young J., Jenkins M.A., Hopper J.L., Baron J.A. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol. Biomarkers Prev. 2008, 17:3208-3215.
191. Queiroz C., Silva T.C., Alves V.A., Villa L.L., Costa M.C., Travassos A.G., Filho J.B., Studart E., Cheto T., de Freitas L.A. P16(INK4a) expression as a potential prognostic marker in cervical pre-neoplastic and neoplastic lesions. Pathol. Res. Pract. 2006, 202:77-83.
192. Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., Vanrumbeke M., Fenaux P. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 91:2985-2990.
193. Rabinowits G., Gerçel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: A diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10:42-46.
194. Rachmilewitz J., Goshen R., Ariel I., Schneider T., de Groot N., Hochberg A. Parental imprinting of the human H19 gene. FEBS Lett. 1992, 309:25-28.
195. Rainier S., Johnson L.A., Dobry C.J., Ping A.J., Grundy P.E., Feinberg A.P. Relaxation of imprinted genes in human cancer. Nature 1993, 362:747-749.
196. Raponi M., Dossey L., Jatkoe T., Wu X., Chen G., Fan H., Beer D.G. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009, 69:5776-5783.
197. Raveh T., Berissi H., Eisenstein M., Spivak T., Kimchi A. A functional genetic screen identifies regions at the C-terminal tail and death-domain of death-associated protein kinase that are critical for its proapoptotic activity. Proc. Natl. Acad. Sci. USA 2000, 97:1572-1577.
198. Raveh T., Droguett G., Horwitz M.S., DePinho R.A., Kimchi A. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat. Cell Biol. 2001, 3:1-7.
199. Riccio A., Sparago A., Verde G., De Crescenzo A., Citro V., Cubellis M.V., Ferrero G.B., Silengo M.C., Russo S., Larizza L., et al. Inherited and Sporadic Epimutations at the IGF2-H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumor. Endocr. Dev. 2009, 14:1-9.
200. Rivera A.L., Pelloski C.E., Gilbert M.R., Colman H., De La Cruz C., Sulman E.P., Bekele B.N., Aldape K.D. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010, 12:116-121.
201. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6:597-610.
202. Roldo C., Missiaglia E., Hagan J.P., Falconi M., Capelli P., Bersani S., Calin G.A., Volinia S., Liu C.G., Scarpa A., et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24:4677-4684.
203. Roman-Gomez J., Jimenez-Velasco A., Agirre X., Cervantes F., Sanchez J., Garate L., Barrios M., Castillejo J.A., Navarro G., Colomer D., et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 2005, 24:7213-7223.
204. Roman-Gomez J., Jimenez-Velasco A., Agirre X., Castillejo J.A., Navarro G., San Jose-Eneriz E., Garate L., Cordeu L., Cervantes F., Prosper F., et al. Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia. Leuk. Res. 2008, 32:487-490.
205. Rosenbaum E., Hoque M.O., Cohen Y., Zahurak M., Eisenberger M.A., Epstein J.I., Partin A.W., Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res. 2005, 11:8321-8325.
206. Russell S.E., Hall P.A. Do septins have a role in cancer?. Br. J. Cancer 2005, 93:499-503.
207. Russell S.E., McIlhatton M.A., Burrows J.F., Donaghy P.G., Chanduloy S., Petty E.M., Kalikin L.M., Church S.W., McIlroy S., Harkin D.P., et al. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res. 2000, 60:4729-4734.
208. Safar A.M., Spencer H., Su X., Coffey M., Cooney C.A., Ratnasinghe L.D., Hutchins L.F., Fan C.Y. Methylation profiling of archived non-small cell lung cancer: A promising prognostic system. Clin. Cancer Res. 2005, 11:4400-4405.
209. Saito Y., Kanai Y., Nakagawa T., Sakamoto M., Saito H., Ishii H., Hirohashi S. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int. J. Cancer 2003, 105:527-532.
210. Saito K., Kawakami K., Matsumoto I., Oda M., Watanabe G., Minamoto T. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin. Cancer Res. 2010, 16:2418-2426.
211. Sarkar F.H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat. 2010, 10.1016/j.drup. 2010.02.001.
212. Sarver A.L., French A.J., Borralho P.M., Thayanithy V., Oberg A.L., Silverstein K.A., Morlan B.W., Riska S.M., Boardman L.A., Cunningham J.M., et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009, 9:401.
213. Sassaman D.M., Dombroski B.A., Moran J.V., Kimberland M.L., Naas T.P., DeBerardinis R.J., Gabriel A., Swergold G.D., Kazazian H.H. Many human L1 elements are capable of retrotransposition. Nat. Genet. 1997, 16:37-43.
214. Sathyanarayana U.G., Padar A., Suzuki M., Maruyama R., Shigematsu H., Hsieh J.T., Frenkel E.P., Gazdar A.F. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 2003, 9:6395-6400.
215. Satoh A., Toyota M., Itoh F., Sasaki Y., Suzuki H., Ogi K., Kikuchi T., Mita H., Yamashita T., Kojima T., et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 2003, 63:8606-8613.
216. Satzger I., Mattern A., Kuettler U., Weinspach D., Voelker B., Kapp A., Gutzmer R. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer 2010, 126:2553-2562.
217. Schaefer A., Jung M., Mollenkopf H.J., Wagner I., Stephan C., Jentzmik F., Miller K., Lein M., Kristiansen G., Jung K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010, 126:1166-1176.
218. Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., Yuen S.T., Chan T.L., Kwong D.L., Au G.K., et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
219. Schulmann K., Sterian A., Berki A., Yin J., Sato F., Xu Y., Olaru A., Wang S., Mori Y., Deacu E., et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005, 24:4138-4148.
220. Scott M., Hyland P.L., McGregor G., Hillan K.J., Russell S.E.H., Hall P.A. Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumors. Oncogene 2005, 24:4688-4700.
221. Seike M., Gemma A., Hosoya Y., Hemmi S., Taniguchi Y., Fukuda Y., Yamanaka N., Kudoh S. Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53. Clin. Cancer Res. 2000, 6:4307-4313.
222. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
223. Shames D.S., Girard L., Gao B., Sato M., Lewis C.M., Shivapurkar N., Jiang A., Perou C.M., Kim Y.H., Pollack J.R., et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006, 3:e486.
224. Shen W.W., Wu J., Cai L., Liu B.Y., Gao Y., Chen G.Q., Fu G.H. Expression of anion exchanger 1 sequestrates p16 in the cytoplasm in gastric and colonic adenocarcinoma. Neoplasia 2007, 9:812-819.
225. Shen L., Kantarjian H., Guo Y., Lin E., Shan J., Huang X., Berry D., Ahmed S., Zhu W., Pierce S., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. Clin. Oncol. 2010, 28:605-613.
226. Shibata S., Yokota T., Wutz A. Synergy of Eed and Tsix in the repression of Xist gene and X-chromosome inactivation. EMBO J. 2008, 27:1816-1826.
227. Shim Y.H., Kang G.H., Ro J.Y. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab. Invest. 2000, 80:689-695.
228. Shirahata A., Sakata M., Sakuraba K., Goto T., Mizukami H., Saito M., Ishibashi K., Kigawa G., Nemoto H., Sanada Y., et al. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res. 2009, 29:279-281.
229. Si M.L., Zhu S., Wu H., Lu Z., Wu F., Mo Y.Y. miR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
230. Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., Juul N., Leong C.O., Calogrias D., Buraimoh A., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J. Clin. Oncol. 2010, 28:1145-1153.
231. Simpkins S.B., Bocker T., Swisher E.M., Mutch D.G., Gersell D.J., Kovatich A.J., Palazzo J.P., Fishel R., Goodfellow P.J. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum. Mol. Genet. 1999, 8:661-666.
232. Slaby O., Svoboda M., Fabian P., Smerdova T., Knoflickova D., Bednarikova M., Nenutil R., Vyzula R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 7:397-402.
233. Sørensen K.D., Wild P.J., Mortezavi A., Adolf K., Tørring N., Heebøll S., Ulhøi B.P., Ottosen P., Sulser T., Hermanns T., et al. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin. Cancer Res. 2009, 15:1400-1410.
234. Stamatopoulos B., Meuleman N., Haibe-Kains B., Saussoy P., Van Den Neste E., Michaux L., Heimann P., Martiat P., Bron D., Lagneaux L. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009, 113:5237-5245.
235. Steensma D.P., Baer M.R., Slack J.L., Buckstein R., Godley L.A., Garcia-Manero G., Albitar M., Larsen J.S., Arora S., Cullen M.T., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial. J. Clin. Oncol. 2010, 27:3842-3848.
236. Stone A.R., Bobo W., Brat D.J., Devi N.S., Van Meir E.G., Vertino P.M. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am. J. Pathol. 2004, 165:1151-1161.
237. Strathdee G., MacKean M.J., Illand M., Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999, 18:2335-2341.
238. Suh M.R., Lee Y., Kim J.Y., Kim S.K., Moon S.H., Lee J.Y., Cha K.Y., Chung H.M., Yoon H.S., Moon S.Y., et al. Human embryonic stem cells express a unique set of microRNAs. Dev. Biol. 2004, 270:488-498.
239. Sun Y., Deng D., You W.C., Bai H., Zhang L., Zhou J., Shen L., Ma J.L., Xie Y.Q., Li J.Y. Methylation of p16 CpG islands associated with malignant transformation of gastric dysplasia in a population-based study. Clin. Cancer Res. 2004, 10:5087-5093.
240. Suter C.M., Martin D.I.K., Ward R.L. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 2004, 36:497-501.
241. Svoboda M., Izakovicova Holla L., Sefr R., Vrtkova I., Kocakova I., Tichy B., Dvorak J. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int. J. Oncol. 2008, 33:541-547.
242. Swisher E.M., Gonzalez R.M., Taniguchi T., Garcia R.L., Walsh T., Goff B.A., Welcsh P. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol. Cancer 2009, 8:48.
243. Symer D.E., Connelly C., Szak S.T., Caputo E.M., Cost G.J., Parmigiani G., Boeke J.D. Human l1 retrotransposition is associated with genetic instability in vivo. Cell 2002, 110:327-338.
244. Szafranska A.E., Davison T.S., Shingara J., Doleshal M., Riggenbach J.A., Morrison C.D., Jewell S., Labourier E. Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. J. Mol. Diagn. 2008, 10:415-423.
245. Tada Y., Wada M., Taguchi K., Mochida Y., Kinugawa N., Tsuneyoshi M., Naito S., Kuwano M. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 2002, 62:4048-4053.
246. Takai D., Gonzales F.A., Tsai Y.C., Thayer M.J., Jones P.A. Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum. Mol. Genet. 2001, 10:2619-2626.
247. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64:3753-3756.
248. Takaoka A.S., Kakiuchi H., Itoh F., Hinoda Y., Kusano M., Ohara M., Tsukakoshi H., Hosokawa M., Imai K. Infrequent alterations of the p16 (MTS-1) gene in human gastric cancer. Tumour Biol. 1997, 18:95-103.
249. Tan A.C., Jimeno A., Lin S.H., Wheelhouse J., Chan F., Solomon A., Rajeshkumar N.V., Rubio-Viqueira B., Hidalgo M. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol. Oncol. 2009, 3:425-438.
250. Tanemura A., Terando A.M., Sim M.S., van Hoesel A.Q., de Maat M.F., Morton D.L., Hoon D.S. CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res. 2009, 15:1801-1807.
251. Tang X., Khuri F.R., Lee J.J., Kemp B.L., Liu D., Hong W.K., Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage-I non-small-cell lung cancer. J. Natl. Cancer Inst. 2000, 92:1511-1516.
252. Tänzer M., Balluff B., Distler J., Hale K., Leodolter A., Röcken C., Molnar B., Schmid R., Lofton-Day C., Schuster T., et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE 2010, 5:e9061. 10.1371/journal.pone.0009061.
253. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110:13-21.
254. Thorvaldsen J.L., Duran K.L., Bartolomei M.S. Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev. 1998, 12:3693-3702.
255. Tien H.F., Tang J.H., Tsay W., Liu M.C., Lee F.Y., Wang C.H., Chen Y.C., Shen M.C. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: It can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br. J. Haematol. 2001, 112:148-154.
256. Tomizawa Y., Iijima H., Nomoto T., Iwasaki Y., Otani Y., Tsuchiya S., Saito R., Dobashi K., Nakajima T., Mori M. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer 2004, 46:305-312.
257. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96:8681-8686.
258. Toyota M., Ahuja N., Suzuki H., Itoh F., Ohe-Toyota M., Imai K., Baylin S.B., Issa J.P. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999, 59:5438-5442.
259. Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., Konishi H., Morimura R., Deguchi K., Fujiwara H., et al. Circulating microRNAs in plasma of patients with gastric cancers. Br. J. Cancer 2010, 102:1174-1179.
260. Tufarelli C., Stanley J.A., Garrick D., Sharpe J.A., Ayyub H., Wood W.G., Higgs D.R. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat. Genet. 2003, 34:157-165.
261. Tzao C., Tung H.J., Jin J.S., Sun G.H., Hsu H.S., Chen B.H., Yu C.P., Lee S.C. Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod. Pathol. 2009, 22:252-260.
262. Ueda T., Volinia S., Okumura H., Shimizu M., Taccioli C., Rossi S., Alder H., Liu C.G., Oue N., Yasui W., et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11:136-146.
263. Umetani N., Takeuchi H., Fujimoto A., Shinozaki M., Bilchik A.J., Hoon D.S. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin. Cancer Res. 2004, 10:7475-7483.
264. Usadel H., Brabender J., Danenberg K.D., Jerónimo C., Harden S., Engles J., Danenberg P.V., Yang S., Sidransky D. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 2002, 62:371-375.
265. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 2005, 5:223-231.
266. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
267. Valastyan S., Reinhardt F., Benaich N., Calogrias D., Szász A.M., Wang Z.C., Brock J.E., Richardson A.L., Weinberg R.A. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032-1046.
268. Vidal D.O., Paixão V.A., Brait M., Souto E.X., Caballero O.L., Lopes L.F., Vettore A.L. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk. Res. 2007, 31:175-181.
269. Vielhauer V., Sarafoff M., Gais P., Rabes H.M. Cell type-specific induction of O6-alkylguanine-DNA alkyltransferase mRNA expression in rat liver during regeneration, inflammation and preneoplasia. J. Cancer Res. Clin. Oncol. 2001, 127:591-602.
270. Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 2009, 41:843-848.
271. Walther A., Houlston R., Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: A meta-analysis. Gut 2008, 57:941-950.
272. Wang J.S., Guo M., Montgomery E.A., Thompson R.E., Cosby H., Hicks L., Wang S., Herman J.G., Canto M.I. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am. J. Gastroenterol. 2009, 104:2153-2160.
273. Wang J., Chen J., Chang P., LeBlanc A., Li D., Abbruzzesse J.L., Frazier M.L., Killary A.M., Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila Pa). 2009, 2:807-813.
274. Watanabe Y., Ueda H., Etoh T., Koike E., Fujinami N., Mitsuhashi A., Hoshiai H. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res. 2007, 27(3B):1449-1452.
275. Watts G.S., Pieper R.O., Costello J.F., Peng Y.M., Dalton W.S., Futscher B.W. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol. Cell. Biol. 1997, 17:5612-5619.
276. Weichert W., Röske A., Gekeler V., Beckers T., Ebert M.P., Pross M., Dietel M., Denkert C., Röcken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncol. 2008, 9:139-148.
277. Weichert W., Röske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F.R., Niesporek S., Denkert C., Dietel M., et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 2008, 98:604-610.
278. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., Kang G.H., Widschwendter M., Weener D., Buchanan D., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006, 38:787-793.
279. Weksberg R., Shuman C., Beckwith J.B. Beckwith-Wiedemann syndrome. Eur. J. Hum. Genet. 2010, 18:8-14.
280. Woodson K., O'Reilly K.J., Ward D.E., Walter J., Hanson J., Walk E.L., Tangrea J.A. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 2006, 1:183-186.
281. Wu M.S., Shun C.T., Sheu J.C., Wang H.P., Wang J.T., Lee W.J., Chen C.J., Wang T.H., Lin J.T. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: With respect to histological subtypes and stages. J. Gastroenterol. Hepatol. 1998, 13:305-310.
282. Wu J., Qin Y., Li B., He W.Z., Sun Z.L. Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. Genomics 2008, 91:443-450.
283. Xi Y., Formentini A., Chien M., Weir D.B., Russo J.J., Ju J., Kornmann M., Ju J. Prognostic values of microRNAs in colorectal cancer. Biomark. Insights 2006, 2:113-121.
284. Xiang S., Liu Z., Zhang B., Zhou J., Zhu B.D., Ji J., Deng D. Methylation status of individual CpG sites within Alu elements in the human genome and Alu hypomethylation in gastric carcinomas. BMC Cancer 2010, 10:44.
285. Xu J., Wang H.L., Lu G.C., Wang Z.J., Lin X., Zhou H.W. Clinical significance of detection of tumor suppressor genes aberrant methylation in cervical carcinoma tissue. Zhonghua Fu Chan Ke Za Zhi 2007, 42:394-397.
286. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., Zeng Y.X., Shao J.Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
287. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
288. Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., Liang S., Leminen A., Deng S., Smith L., et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008, 68:10307-10314.
289. Yang Q., Zage P., Kagan D., Tian Y., Seshadri R., Salwen H.R., Liu S., Chlenski A., Cohn S.L. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin. Cancer Res. 2004, 10:8493-8500.
290. Yanokura M., Banno K., Kawaguchi M., Hirao N., Hirasawa A., Susumu N., Tsukazaki K., Aoki D. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol. Rep 2007, 17:41-48.
291. Yates D.R., Rehman I., Abbod M.F., Meuth M., Cross S.S., Linkens D.A., Hamdy F.C., Catto J.W. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 2007, 13:2046-2053.
292. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., Zahurak M., Piantadosi S., Walsh P.C., Bova G.S., De Marzo A.M., Isaacs W.B., Nelson W.G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004, 64:1975-1986.
293. Yegnasubramanian S., Haffner M.C., Zhang Y., Gurel B., Cornish T.C., Wu Z., Irizarry R.A., Morgan J., Hicks J., DeWeese T.L., et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008, 68:8954-8967.
294. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., Huang Y., Hu X., Su F., Lieberman J., Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
295. Yu J., Zhu T., Wang Z., Zhang H., Qian Z., Xu H., Gao B., Wang W., Gu L., Meng J., et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin. Cancer Res. 2007, 13:7296-7304.
296. Yu S.L., Chen H.Y., Chang G.C., Chen C.Y., Chen H.W., Singh S., Cheng C.L., Yu C.J., Lee Y.C., Chen H.S., et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13:48-57.
297. Yu W., Gius D., Onyango P., Muldoon-Jacobs K., Karp J., Feinberg A.P., Cui H. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008, 451:202-206.
298. Zenz T., Mohr J., Eldering E., Kater A.P., Bühler A., Kienle D., Winkler D., Dürig J., van Oers M.H., Mertens D., et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009, 113:3801-3808.
299. Zhang X., Xu H.J., Murakami Y., Sachse R., Yashima K., Hirohashi S., Hu S.X., Benedict W.F., Sekiya T. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res. 1994, 54:4177-4182.
300. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., Liang S., Naylor T.L., Barchetti A., Ward M.R., et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA 2006, 103:9136-9141.
301. Zhu S., Si M.L., Wu H., Mo Y.Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 2007, 282:14328-14336.